This inventor holds 3 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignee: The University of Texas System. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: Gregory Lizée: Innovator in Immunotherapy
Introduction
Gregory Lizée is a prominent inventor based in Houston, TX (US), known for his significant contributions to the field of immunotherapy. With a focus on T cell receptors, his work aims to advance cancer treatment methodologies. He holds 3 patents that reflect his innovative approach to tackling complex medical challenges.
Latest Patents
One of Gregory Lizée's latest patents involves T cell receptors for immunotherapy. This patent provides T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat cancers including cutaneous melanoma, uveal melanoma, mucosal melanoma, or metastatic melanoma. Additionally, methods for expanding a population of T cells that target SLC45A2 are also included in this patent. Another significant patent focuses on HLA-restricted VGLL1 peptides and their use in promoting an immune response in a subject. This patent outlines tumor-antigen VGLL1 specific peptides and methods for generating VGLL1-specific T cells, which can be used for cancer treatment. Furthermore, the VGLL1-specific peptides may serve as a vaccine.
Career Highlights
Gregory Lizée is affiliated with the University of Texas System, where he continues to push the boundaries of cancer research and immunotherapy. His work is characterized by a commitment to developing innovative solutions that can improve patient outcomes.
Collaborations
Gregory collaborates with esteemed colleagues such as Cassian Yee and Janos Roszik, who share his passion for advancing cancer therapies through innovative research.
Conclusion
Gregory Lizée's contributions to immunotherapy exemplify the impact of innovative thinking in the medical field. His patents and ongoing research hold promise for improving cancer treatment options and enhancing patient care.